<DOC>
	<DOCNO>NCT00091091</DOCNO>
	<brief_summary>RATIONALE : Assessing long-term effect cancer treatment cancer survivor may help improve ability plan effective treatment follow-up care . PURPOSE : This clinical trial study long-term effect treatment patient previously treat childhood Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Long-Term Effects Treatment Patients Previously Treated Childhood Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine cumulative incidence characterize spectrum select adverse physiologic psychosocial outcome , use self-report clinical evaluation , patient previously treat childhood Hodgkin 's lymphoma . - Compare cumulative incidence spectrum self-reported adverse outcome patient , use data collect comparable time period diagnosis , Hodgkin 's lymphoma survivor Childhood Cancer Survivor Study ( CCSS ) . - Compare self-reported health-related outcome outcomes detect clinical evaluation medical record review group patient . OUTLINE : This cohort , cross-sectional , multicenter study . - Contemporary group : Patients complete self-report long-term outcome questionnaire comprehensive psychosocial questionnaire . A medical record review perform . Patients undergo comprehensive risk-based clinical evaluation specific examination study base upon Children 's Oncology Group Late Effects Screening Guidelines patient ' specific therapeutic exposure . - Childhood Cancer Survivor Study ( CCSS ) group : Patients undergo telephone interview medical record review validate select self-reported long-term outcome . Patient reply baseline CCSS questionnaire ( complete certain timepoints diagnosis ) review target long-term outcome . PROJECTED ACCRUAL : Approximately 1,000 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Contemporary cohort At least 5 year since diagnosis Hodgkin 's lymphoma Diagnosed year 19872001 21 diagnosis No evidence disease Prior treatment 1 follow protocol year 19872001 : Children 's Cancer Group ( CCG ) CCG5942 , CCG59704 Pediatric Oncology Group ( POG ) POG8625 , POG8725 , POG9425 , POG9426 Pediatric Hodgkin 's Consortium : VAMP , VEPA , VAMP/COP Institutional protocol COPP/ABV , MOPP/ABVD , ABVD Childhood Cancer Survivor Study ( CCSS ) Hodgkin 's lymphoma cohort Current enrollment CCSS Diagnosed year 19761986 Completed baseline questionnaire comparable timepoints ( contemporary cohort ) diagnosis PATIENT CHARACTERISTICS : Age Any age Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>long-term effect secondary cancer therapy child</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
</DOC>